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Available online 13 January 2016Despite the emergence of JAK inhibitors, there is a need for disease-modifying treatments for Philadelphia-negative
myeloproliferative neoplasms (MPNs). JAK inhibitors ameliorate symptoms and address splenomegaly, but because
of the heterogeneous contributors to the disease process, JAK inhibitor monotherapy incompletely addresses the
burden of disease. The ever-growing understanding of MPN pathogenesis has provided the rationale for testing
novel and targeted therapeutic agents, as monotherapies or in combination, in preclinical and clinical settings. A
number of intriguing options have emerged, and it is hoped that further progress will lead to signiﬁcant changes
in the natural history of MPNs.
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The Philadelphia chromosome-negative (Ph−) MPNs include clonal
disorders of myeloid progenitor cells, such as polycythemia vera (PV),
essential thrombocythemia (ET), and myeloﬁbrosis (MF). The latter can
be sub-categorized as either primary (PMF) or as transformed from PV
or ET (post-PV/ET MF) (Tefferi et al., 2009a). The incidence of classic
Ph− MPNs in Europe is 1.8 cases per 100,000 person-years (Visser
et al., 2012). In the US, between 2008 and 2010 (as assessed by a review
of two large health plans), the prevalences of PV, ET, andMFwere 44–57,
38–57, and 4–6 per 100,000, respectively (Mehta et al., 2012). In general,
the MPNs may be associated with an increased risk of morbidity and
mortality and may lead to a signiﬁcant decrement in quality of life
(QOL). Generally, MF differs from PV and ET in that it typically carries a
worse prognosis and high symptom burden related to elevated cytokine
levels, cytopenias, splenomegaly, and extramedullary hematopoiesis, all
of which can result in fatigue, early satiety, abdominal discomfort, inac-
tivity, night sweats, pruritus, bone pain and weight loss (Emanuel et al.,
2012). Transformation to acute myelogenous leukemia (AML) has been
the most feared complication of MPNs, particularly of MF.Fig. 1. JAK-STAT signaling contributes to the pathogenesis of MPNs. Unregulated JAK-STAT s
pathway, may result from a number of aberrations including point mutations JAK2 V617F, lea
the thrombopoietin receptor. Number small molecule inhibitors of these pathways, includin
Janus kinase; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide-3 kinase; STAT,Prognosis of MPNs varies greatly based on subtype. ET is associated
with a 10-year and 15-year survival of 89 and 80%, leukemic transfor-
mation rate of 0.7% and 2.1%, and rate of progression to MF of 0.8%
and 9.3%, respectively (Barbui et al., 2011). Among patients with PV,
median survival has been shown to be 14.1 years, which is worse than
that of the age- and sex-matched control population of the US (Tefferi
et al., 2013). Evolution to MDS and leukemia was the main cause of
death in a phase 3 study comparing the use of hydroxyurea (HU) to
pibobroman among treatment-naïve PV patients under the age of
65 years (Kiladjian et al., 2011) In a large European epidemiological
study of PV, 41% of deaths (1.5 deaths per 100 persons per year) were
attributable to cardiovascular events (Marchioli et al., 2005). Themedi-
an survival for patients with MF was shown to be 6.5 years, between
years 1996 and 2007, in a European population (Cervantes et al., 2012).
A better understanding of the molecular pathogenesis of Ph−MPNs
has been greatly facilitated by the 2005 discovery of the point mutation
JAK2 V617F, which is present in almost 95% of PV cases and 50–60% of
ET and PMF cases (Kralovics et al., 2005; Rampal and Levine, 2014). The
mutation leads to constitutive activation of Janus kinase 2 (JAK2), amem-
ber of the Janus family of kinases, normally phosphorylated/activated byignaling, leading to STAT-mediated hematopoiesis and activation of the PI3K/Akt/mTOR
ding to constitutive activation of JAK2 kinase, and MPL W515L, an activating mutation of
g JAK, PI3K, and mTOR inhibitors, are in clinical development. Epo, erythropoietin; JAK,
signal transducer and activator of transcription; Tpo, thrombopoietin; -i, inhibitor.
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scription (STAT) pathways in hematopoiesis (Fig. 1). The thrombopoietin
receptor mutation MPLW515L, identiﬁed shortly after the discovery of
JAK2 V617F, is another driver mutation that leads to activation of the
JAK–STAT pathway and is present in a minority JAK2 V617F-negative
cases of MF and ET (Pikman et al., 2006). In 2013, mutations of CALR,
the gene that encodes the endoplasmic reticulum chaperone calreticulin,
were identiﬁed among67–88%of patientswith JAK2/MPLnegative ET and
MF (Klampﬂ et al., 2013; Nangalia et al., 2013). The presence of thesemu-
tations may have prognostic implications for patients. For example, MF
patients with CALRmutations have an improved overall survival as com-
pared to patients with JAK2 mutations (Klampﬂ et al., 2013; Nangalia
et al., 2013), and ET patients with CALRmutations have a decreased inci-
dence of thrombosis (Rumi et al., 2014a). The absence of mutations of
JAK2, CALR, andMPL (“triple negative” PMF) appears to ultimately pro-
mote leukemic transformation, as compared with CALR-mutated or
JAK2-mutated patients (Rumi et al., 2014b). These ﬁndings suggest that
mutational statusmay be able to serve as a prognosticator independently
from established prognostic models that are based on clinical features.
Since the discovery of JAK2V617F, there has been the identiﬁcation of nu-
merous other somatic mutations in MPNs (e.g., JAK2 exon 12, IKZF1,
DNMT3A, TP53, TET2, SRSF2, SF3B1, ASXL1, IDH1/2, and EZH2). Many of
these genes play roles in epigenetic processes, leading to activation or
suppression of gene expression, suggesting a rationale for epigenetic
therapies. Among MF patients, mutations in ASXL1, SRSF2, IDH, or
EZH2 have been associated with a poor survival or an increased risk
for leukemic transformation (Vannucchi et al., 2013). Many of the
other mutations seen in MPNs involve mRNA splicing and genes con-
trolling cellular metabolism, and some may facilitate clonal selection
and promote dominance of JAK2 V617F subclones (Nangalia and
Green, 2014; Vainchenker et al., 2011). The role of systematicmutation-
al proﬁling to predict for beneﬁt to therapy is the subject of current in-
vestigations, whichwill likely be challenging endeavors given the clonal
complexity of MPNs (Lundberg et al., 2014).
2. Current Treatment of Classic Ph−MPNs
Treatment decisions are generally based on MPN subtype, risk cate-
gory, age, and disease manifestations. For PV and ET, thrombosis risk
category often guides the decision to use cytoreductive and anti-
platelet therapies (and phlebotomy for PV). Historically, treatment of
MF has been guided by the patient's symptomproﬁle and burden of dis-
ease, and has involvedmanaging cytopenias (androgens, erythropoiesis
stimulating agents, immunomodulatory agents) and splenomegaly
(HU, busulfan, cladribine, splenectomy, splenic radiation, and immuno-
modulatory agents) and providingmeasures to prevent infections, con-
trol symptoms, and improve QOL (e.g., corticosteroids and stimulants)
(Gowin et al., 2013; Tefferi et al., 2009b). Treatment has also been
based in part on the risk category (as an aid for selecting transplant can-
didates), assessed by the International Prognostic Scoring System (IPSS)
or Dynamic IPSS/plus. Allogeneic hematopoietic stem cell transplant,
typically reserved for ﬁt patients with intermediate-2 or high-risk
disease, is the only curative treatment option and may resolve bone
marrow ﬁbrosis, lead to molecular remission, restore normal hemato-
poiesis, and lead to cure in 40–70% of patients (Kröger et al., 2009;
Ballen et al., 2010). However, its association with signiﬁcant morbidity
and mortality limits its utility.
The oral selective JAK1/2 inhibitor ruxolitinibwas assessed in a phase
1/2 study of 153 MF patients requiring therapy, identifying 25 mg orally
twice daily or 100mg once daily as themaximum tolerated doses, along
with evidence of dose-dependent suppression of phosphorylated STAT3
(Verstovsek et al., 2010). In the phase 2 portion, based on responses
(at least 50% reduction of splenomegaly), toxicity, and need for dose re-
ductions, 15mg twice-dailywas established as the optimal starting dose,
and most patients experienced rapid improvement in debilitating
MF-related symptoms. Ruxolitinib was FDA- and EMA-approved forthe treatment of MF in 2011 and 2012, respectively, based on the results
of two phase 3 studies in which ruxolitinib was compared to either pla-
cebo (COMFORT-1) or to best available therapy (COMFORT-2)
(Verstovsek et al., 2012; Harrison et al., 2012). Among the ruxolitinib-
treated patients, a 35% or higher reduction in spleen size was achieved
and maintained in 41.9% (versus 0.7% of placebo-treated patients) at
week 24 in COMFORT-1 and in 32% and 28% (versus 0% of patients
who received best available therapy) at weeks 24 and 48, respectively,
in COMFORT-2. Moreover, in COMFORT-1, 45.9% of ruxolitinib-treated
patients (versus 5.3%) achieved an improvement of at least 50% in the
total symptom score (Verstovsek et al., 2012). In COMFORT-2, pre-
speciﬁed exploratory analyses showed that ruxolitinib-treated patients
experienced improvements in quality of life, role functioning, and phys-
ical condition and reductions in MF-associated symptoms as compared
to the patients who received best available therapy (Harrison et al.,
2012). The efﬁcacy of ruxolitinib appeared to be dose-dependent and
was not inﬂuenced by the presence or absence of the JAK2 V617F muta-
tion, as patients with mutant and wild-type JAK2 responded similarly.
Extended follow-up of these two studies demonstrated a survival advan-
tage with the use of ruxolitinib among intermediate- and high-risk MF
patients, while reduction in spleen size seemed to correlate with longer
survival (Cervantes et al., 2013; Vannucchi et al., 2015a). In the UK
open-label, phase 2 ROBUST trial, involving 48 MF patients, 50% of all
patients and 57% of intermediate-1 risk patients achieved the primary
composite endpoint of treatment success, whichwas deﬁned as ≥50% re-
duction in palpable spleen length and/or a ≥50% decrease in the Myelo-
ﬁbrosis Symptom Assessment Form Total Symptom Score at 48 weeks
(Mead et al., 2015). An exploratory analysis of COMFORT-1 showed a re-
duction in MF-related hepatomegaly among the ruxolitinib-treated pa-
tients, providing rationale for using ruxolitinib in MF patients who
undergo splenectomy (Verstovsek et al., 2015). There are also reports
of resolution of marrow ﬁbrosis, reduction in JAK2 mutant allele burden,
and even achievement of complete molecular remission with its long-
term use (Wilkins et al., 2013; Deininger et al., 2015).
Ruxolitinib's FDA and EMA approvals were expanded in 2014 and
2015, respectively, to the treatment of PV patients who are intolerant
of or resistant to HU, based on results from the RESPONSE trial, a
phase 3 trial in which ruxolitinib was shown to be superior in regard
to hematocrit control and spleen volume reduction as well as in sup-
pressing disease-related symptoms (Vannucchi et al., 2015b). The
most common adverse events, albeit usually low-grade, associated
with ruxolitinib are anemia and thrombocytopenia, and other reported
adverse events include headache, fatigue, diarrhea, nausea, and infec-
tions (Verstovsek et al., 2012; Harrison et al., 2012; Vannucchi et al.,
2015b). Progressive multifocal leukoencephalopathy has been reported
to occur in an elderly patient receiving the drug (Wathes et al., 2013).
The infectious complications of ruxolitinib may be at least partially ex-
plained by its impairment of dendritic cell development and function, in-
cluding impairment of the dendritic cell's activation, migration, and
ability to induce T-cell responses (Heine et al., 2013b). These observations
have prompted some investigators to recommend an infectious risk as-
sessment and prophylaxis strategy (Heine et al., 2013a). Three-year fol-
low-up of the COMFORT studies showed that the rates of many of the
adverse events generally decreased with longer exposure to ruxolitinib
treatment, with the highest rates occurring within the ﬁrst 6 months
(Cervantes et al., 2013). It is also important to keep in mind that sudden
withdrawal of ruxolitinib has been associatedwith a shock-like syndrome
from the reemergence of suppressed inﬂammatory cytokines (Tefferi and
Pardanani, 2011). However, such a severe withdrawal syndromewas not
reported in the COMFORT and RESPONSE studies, but return of baseline
MF-related symptoms typically occurs within approximately a week
upon discontinuation of ruxolitinib (Verstovsek et al., 2012; Harrison
et al., 2012; Vannucchi et al., 2015b).
In assessing ruxolitinib's position in the grand scheme of MPN treat-
ment, two critical appraisals of the data from both the COMFORT trials
suggested that the evidence to support ruxolitinib for the treatment of
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sample size, comparator choice, and outcome indirectness (Barosi
et al., 2015; Marti-Carvajal et al., 2015). Alternatively, an argument
could be made that the data to support ruxolitinib's role in the treat-
ment of MPNs are derived from randomized controlled trials with a rel-
atively large sample size for an orphan disease, particularly one inwhich
there is a paucity of other effective therapies.
To further deﬁne ruxolitinib's role, cost effectiveness studies have
been conducted. The National Institute for Health and Care Excellence
(NICE) obtained clinical and cost-effectiveness data from the drugmanu-
facturer (derived from COMFORT-1 and COMFORT-2), andwith this data,
an independent study group concluded that there was signiﬁcant uncer-
tainty of the manufacturer's cost-effectiveness model due to its limita-
tions. Despite conceding that ruxolitinib was clinically effective, NICE
decided that ruxolitinib was not a cost effective use of National Health
Service resources for treatment MF-related splenomegaly or disease
symptoms in adults (Wade et al., 2013). A Finnish study assessed the
cost effectiveness of ruxolitinib for the treatment of MF by creating a
survival-based decision model based on data from COMFORT-2 and
found that ruxolitinib produced 2.43 incremental quality-adjusted life
years when compared to best available therapy, concluding that these
gains came at reasonable costs, given the improvements in overall
survival (Hahl et al., 2015).
3. Other JAK Inhibitors
Beyond ruxolitinib, there are other JAK inhibitors under clinical in-
vestigation. The most advanced in development include momelotinib
and pacritinib. As with ruxolitinib, momelotinib is a dual JAK1/2 inhibi-
tor that has been shown to decrease splenomegaly and MPN-related
symptoms in patients with intermediate or high-risk MF (Pardanani
et al., 2013). Based on the International Working Group (IWG) criteria,
59% of evaluable patients in that phase I–II study experienced a re-
sponse to anemia, and 70% of patients who had received red cell trans-
fusions in themonth prior to study entry achieved aminimum12-week
period of transfusion-independence. Grade 3/4 adverse reactions in-
cluded thrombocytopenia in nearly third of the patients, while
treatment-related grade 1 sensory peripheral neuropathy was seen in
about a ﬁfth of the patients. Currently ongoing are randomized studies
of ruxolitinib versus momelotinib in MF patients (NCT01969838) and
momelotinib versus best available therapy among MF patients who
have already been treated with ruxolitinib (NCT02101268).
The other advanced phase JAK inhibitor, pacritinib, is a dual JAK2/
FLT3 kinase inhibitor that has been shown to reduce splenomegaly
and MF-related symptoms (Komrokji et al., 2015). A unique aspect
of this inhibitor is the potential lack of signiﬁcant anemia and throm-
bocytopenia noted with other JAK inhibitors. In a phase 2 study, in
which 35 intermediate/high-risk MF patients were enrolled, 40%
had hemoglobin b10 g/dL and 43% had platelets b100,000 × 109/L
at entry (Komrokji et al., 2015). The percentage change in hemoglo-
bin measurements at each study visit relative to the baseline visit
stayed within a median of 6%. Platelet count measurements de-
creased by a median of 12% at week 12 and 17.6% at week 24, but
these levels remained stable through week 60. Grade 1/2 diarrhea
and nausea were the most common adverse events (AEs). Two ongo-
ing phases 3 trials are comparing pacritinib to best available therapy
(NCT01773187 and NCT02055781).
4. Novel Treatment Strategies: Beyond JAK Inhibitor Monotherapy
Given the limitations of JAK inhibition as monotherapy, such as
its inability to lead to CR in most patients and the prompt return of
symptoms upon treatment discontinuation, there is a signiﬁcant ef-
fort to develop new classes of therapeutic agents for MPNs, many
of which are being studied as combination therapy with ruxolitinib.
Although promising, there are a number of potential challengeswith developing drug combinations for MPN treatment, taking into
account the burgeoning number of putative drug targets and exper-
imental agents in development, the inability to reliably predict syn-
ergist activity in the preclinical setting, relatively low disease
incidence, and the increased complexity of assessing disease re-
sponse and clinical beneﬁt, as compared to that of many other
diseases.5. Interferon
Interferon (IFN) alpha, a cytokine with antiviral, immunomodulato-
ry, and growth inhibitory properties, has been of interest for the treat-
ment of MPNs for decades (Kiladjian et al., 2008a, 2008b). Standard
IFN alpha has been associated with hematologic response rates close
to 80% for PV and ET, but its use is limited by toxicities, such as cytope-
nias, ﬂu-like symptoms, and fatigue, leading to treatment discontinua-
tion in up to 20% of patients. In a multicenter phase 2 study of
pegylated (peg)-IFN alpha-2a involving 40 PV patients, there was a
95% complete hematologic response rate among the evaluable patients
at 12 months and a 90%molecular response, as assessed by JAK2 V617F
allele percentage, which declined from 45% at baseline to 3% after
36 months (Kiladjian et al., 2008a, 2008b). In another phase 2 study of
peg-IFN, complete hematologic responses were achieved in 76% and
77% of patients with PV and ET, respectively, along with complete
molecular response in 18% and 17% (Quintás-Cardama et al., 2013).
However, twenty percent of the patients in this study discontinued the
treatment because of drug-related toxicity. In addition to reductions in
JAK2 V617F allele burden, CALRmutant molecular responses have also
been noted among ET patients treated with peg-IFN (Verger et al.,
2015). The next-generation, mono-pegylated IFN alpha-2b isoform,
ropeginterferon alpha-2b, administered every 2 weeks, was assessed in
a phase 1/2 study involving 51 PV patients, yielding an overall response
rate of 90% and a complete response rate of 47% (Gisslinger et al., 2015).
The complete and partialmolecular response rateswere 47% and 43%, re-
spectively. Overall, interferon treatment has major efﬁcacy in the treat-
ment of PV and ET, while its efﬁcacy in MF is more limited and its role
in MF management not well-deﬁned (Ianotto et al., 2013).6. Epigenetic Therapies
As mentioned, a number of recurrent somatic mutations observed in
MPN are involved with epigenetic processes and include the following:
TET2, involved with methylcytosine residue hydroxylation
(Delhommeau et al., 2009); DNMT3A, a cytosine methyltransferase
(Abdel-Wahab et al., 2011b); IDH1/2, oxidoreductases leading to 2-
hydroxyglutarate production that inhibits alpha-ketoglutarate-
dependent enzymes such as TET2 (Tefferi et al., 2012); ASXL1, involved
with HOX gene regulation via Polycomb repressive complex 2 (PRC2)-
mediated histone methylation (Abdel-Wahab et al., 2012); and EZH2, a
histone methyltransferase component of PRC2 (Abdel-Wahab et al.,
2011a). Of note, JAK2 functions as an epigeneticmodiﬁer by affecting his-
tone posttranslational modiﬁcations. Genome-wide methylation studies
have revealed hyper- and hypomethylation in promoter regions and in
non-CpG island loci amongMPN samples, as comparedwith healthy con-
trols, with differences also noted between PMF and PV/ET samples
(Nischal et al., 2013). Particular methylomic signatures were associated
with the presence of ASXL1 and TET2 mutations. Also supporting the
role of epigenetic aberration in the pathogenesis of MPNs, histone
deacetylase (HDAC) activity has been observed to be elevated in PMF
patients as compared with other MPN patients and healthy volunteers,
with HDAC levels correlating to degree of splenomegaly (Wang et al.,
2008). Global gene expression proﬁling of blood from patients with
MPNs has revealed abnormalities in the expression of various HDAC
genes (Skov et al., 2012).
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Given the abundance of evidence that epigenetic deregulation is in-
volved in MPN pathogenesis, targeting epigenetic processes is of great
therapeutic interest. As a class, the HDAC inhibitors (HDACis), four of
which are currently FDA-approved for use in T-cell lymphomas or mul-
tiple myeloma, along with the DNA methyltransferase inhibitors, have
led the way in epigenetic therapy for the treatment of malignancies.
Histone modiﬁcation patterns, regulated by histone acetyl transferases
and HDACs, guide the recruitment of various transcription factors to
maintain and perform normal cellular functions (Mascarenhas et al.,
2011). Dysregulation of this epigenetic process can result in suppression
of transcription of tumor suppressor and cell differentiation genes,
contributing to MPN pathogenesis (Fig. 2). There have been numerous
preclinical and clinical studies in recent years that have provided
proof of principle that HDAC inhibition confers some degree of anti-
neoplastic activity among MPNs. The HDAC inhibitor givinostat was
found to induce apoptosis in JAK2 V617F MPN cells to a greater degree
than in JAK2wild type cell lines, and global gene expression analysis re-
vealed that it modulated expression of multiple genes that are implicat-
ed in cell cycle regulation and hematopoiesis (Amaru Calzada et al.,
2012). Among MPN cell lines and CD34+ cells from MPN patients,
givinostat inhibited proliferation and erythroid differentiation and in-
creased histoneH3 acetylation at the promoter of NFE2, a gene involved
with hematopoiesis. Furthermore, it independently inhibited JAK–STAT
signaling. In combinationwith hydroxyurea, it synergistically potentiat-
ed the induction of pro-apoptotic effects in the JAK2 V617F MPN cell
lines (Amaru Calzada et al., 2013).
Two other HDAC inhibitors, trichostatin A and vorinostat, were able
to restore expression of miR-375, which is a negative regulator of JAK–
STAT signaling (Yin et al., 2015). Forced expression ofmiR-375 has been
previously shown to inhibit constitutive and inducible JAK2/STAT sig-
naling, suppresses cell proliferation, and decreases colony formation in
hematopoietic progenitors from MPN patients. In a phase 2 study in
which givinostat was administered to JAK2 V617F-mutated PV, ET, and
MF patients (n = 29) starting at 50 mg orally twice daily and givenFig. 2. Examples of other aberrantly regulated molecular signaling pathways and targets in MP
condensation and transcriptional silencing of tumor suppressor genes (Wang et al., 2008). PIM
functions, one of which is phosphorylation and stabilization ofMyc. The BET family of BRD prote
bromodomain and extraterminal family of bromodomain-containing proteins; BRD4, bromo
Moloney virus; STAT, signal transducer and activator of transcription, -i, inhibitor.for a median of 20 weeks, 3 major responses were observed among 16
MF patients (Rambaldi et al., 2010). Among 13 PV/ET patients, 1 com-
plete and 6 partial responses were noted, while pruritus and spleno-
megaly reduction was observed in 75% of PV/ET and 38% of MF
patients. Dose reduction and/or temporary interruption was required
in 10 and 15 of the patients, respectively. In another phase 2 study,
using two different doses of givinostat in combination with
hydroxycarbamide (HC) among PV patients unresponsive to the maxi-
mum tolerated dose (MTD) of HC, complete and partial responses
were observed in 55% and 50% of patients receiving 50 and 100 mg of
givinostat, respectively (Finazzi et al., 2013). Pruritus reduction was
observed in most of the patients. Among 22 intermediate/high-risk
MF patients treated with the HDAC1 inhibitor pracinostat in a phase 2
study, 36% experienced clinical beneﬁt, but 91%, 13%, and 21% experi-
enced fatigue, grade 3/4 neutropenia, and grade 3/4 thrombocytopenia,
respectively. Almost all of the patients discontinued therapy, primarily
due to lack of efﬁcacy (Quintás-Cardama et al., 2012). A phase 2 study
involving 63 ET/PV patients demonstrated a 35% response rate along
with pruritus and splenomegaly reduction and a reduction in JAK2
V617F allelic reduction, but more than half of the patients discontinued
treatmentmainly due to signiﬁcant toxicity, including diarrhea, fatigue,
and renal impairment (Andersen et al., 2013). Similarly, in a phase 2
study of pan-deacetylase inhibitor panobinostat in MF patients, some
evidence of efﬁcacy was noted, but toxicity led to signiﬁcant treatment
discontinuation (Deangelo et al., 2013). Given the seemingly low thera-
peutic index of HDACis for the treatment of MPN, studying HDACis at
lower doses, in combination with other agents may be warranted. As
supported by preclinical studies (Wang et al., 2009; Evrot et al., 2013),
two clinical trials of panobinostat in combination with ruxolitinib for
the treatment of MF are ongoing (NCT01693601 and NCT01433445).
6.2. Hypomethylating Agents
There is a potential role for the other major class of epigenetic mod-
ifying agents, DNA methyltransferase inhibitors, also known as
hypomethylating agents (HMA), in treating MPNs, as evidenced byNs. HDAC-mediated deacetylation of the lysine residues of histone tails lead to chromatin
kinase expression, induced by JAK-STAT signaling, is involved in a number of prosurvival
ins includes BRD4, which has a pocket for acetylated lysine residues of the histone tail. BET,
domain-containing protein 4; HDAC, histone deacetylase; PIM; proviral integration of
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normal CD34+cellswith theHMAdecitabine, followed byHDAC inhib-
itor suberoylanilide hydroxamic acid or trichostatin A resulted in apo-
ptosis in the former but not in the latter (Wang et al., 2010). With
transplantation of HMA/HDAC inhibitor-treated JAK2 V617F+ PMF
CD34+ cells into non-obese diabetic/severe combined immunodeﬁ-
cient mice, the percentage of JAK2 V617F+ cells progressively declined
from 2 to 6 months, in comparison with that of mice transplanted with
cells treatedwith cytokines (Wang et al., 2010). A retrospective study of
45patientswithMPN transformed toAML,MPN in acceleratedphase, or
high-risk PMF treated with decitabine revealed response rates that
ranged from 29% to 82%, response durations of 6.5 to 9 months, and
an improvement in overall survival among responders as compared
with non-responders (Badar et al., 2015). There are clinical trials evalu-
ating the activity of decitabine for patients withMF and high-riskMPNs,
as a single agent and in combinationwith JAK inhibitors (NCT00095784,
NCT02564536, and NCT02076191). Limited clinical activity of 5-
azacitidine was observed in a trial involving 34 MF patients, with a
24% response rate after a median of 5 months of treatment (Quintás-
Cardama et al., 2008). An assay for global DNA methylation showed a
decrease from 53% methylation pre-therapy to 44% on day 14 and a re-
turn to 50% at the end of the ﬁrst 28-day cycle. Trials of azacitidine in
combination with ruxolitinib and with a hedgehog inhibitor are under-
way (NCT01787487 and NCT02129101).
6.3. Bromodomain Inhibition
Bromodomains are a highly conserved protein motif able to recog-
nize acetylated lysine residues of histone and nonhistone proteins and
serve as epigenetic readers and regulators that participate in DNA repli-
cation, chromatin remodeling, DNA damage, and transcriptional regula-
tion (Fig. 2) (Dawson et al., 2012). They exist in a tandem structure at
the N-terminal of more than 40 different human proteins and belong
to one of nine major families, one of which is the bromodomain and
extraterminal (BET) family, comprising bromodomain-containing
proteins 2, 3, 4, and T. Bromodomain 4, for example, is involved with
transcriptional initiation and elongation by associating with mediator
complex andwith positive transcription elongation factor b, respective-
ly (Dawson et al., 2012). Abnormalities involving BET proteins may
contribute to the pathogenesis of a number of malignancies, including
multiple myeloma, Burkitt's lymphoma, AML with MLL translocations,
NUT midline carcinomas, and MPNs (Dawson et al., 2012; Wyspianska
et al., 2014). These observations have prompted ongoing efforts to de-
velop BET inhibitors, which inhibit the ability of BET proteins to interact
with acetylated lysine residues on histones. The BET inhibitor I-BET151
was shown to inhibit growth and, along with a JAK2 inhibitor, induce
apoptosis among JAK2 inhibitor-resistant human erythroleukemic
(HEL) cell lines via downregulation of LMO2, an oncogenic regulator
that is dependent upon JAK2 kinase activity in HEL cells (Wyspianska
et al., 2014). I-BET151 inhibited erythroid colony formation among
JAK2 mutant but not wild-type JAK2 associated erythroid colonies
taken fromPVpatients. Also of particular interest is BET's role in regulat-
ing MYC and that inhibition of BET bromodomain–promoter interac-
tions results in a reduction of MYC transcript and protein levels
resulting in G1 arrest and extensive apoptosis in various leukemia and
lymphoma cell lines (Chan et al., 2015). Currently, two phase 1 trials
assessing BET inhibitors are enrolling patients with myeloproliferative
neoplasms (NCT02158858, NCT02431260).
7. PI3K/Akt/mTOR Pathway Inhibition
Anumber of agents that target various nodes of the phosphoinositide-
3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway,
including PI3K and mTOR inhibitors, are currently in development for
the treatment of MPNs. This pathway is a crucial regulator of cell growth,
survival, and metabolism conditions (Saleiro and Platanias, 2014;Mohindra et al., 2014). It mediates ribosomal translation of mRNA, via
downstream effectors 4EBP1 and S6K, into proteins required for cell
growth, cycle progression, and metabolism. The overactivation of this
pathway, which can be result from constitutive activity of upstream
JAK2 (Fig. 1), has been observed in MPNs, and its various roles in the
pathogenesis of MPNs has been reviewed in detail elsewhere
(Bartalucci et al., 2013a; Pandey and Kapur, 2015; Mclornan and
Harrison, 2013). In brief, the PI3K/Akt/mTOR pathway may mediate dis-
ease progression aswell as cellular drug resistance. The rapalogmTOR in-
hibitor everolimus, currently approved for the treatment of various
advanced solid tumors, was shown to have clinical activity in MF in a
phase 1/2 clinical trial (Guglielmelli et al., 2011). Of 30 evaluable high/
intermediate-risk MF patients who had received prior therapy, spleno-
megaly reduction of N50% and N30% occurred in 20% and 44%, respective-
ly, and 69% and 80% experienced complete resolution of constitutional
symptoms, respectively. The responses were not associated with a re-
duced JAK2V617F allele burden orwith cytokine levels. Grade 1/2 stoma-
titis was themost common toxicity, occurring in themajority of subjects.
Of great clinical interest, based on the results ofmultiple preclinical stud-
ies, is the combination of PI3K/Akt/mTOR inhibitors with JAK inhibitors
(Choong et al., 2013; Bartalucci et al., 2013b; Szymańska et al., 2015).
In a cellular screening assay, synergistic anti-proliferative activity was
observed in JAK2-mutated MPN mouse Ba/F3 cells when subjected to
combinations of various pan-class I PI3K inhibitors and JAK inhibitors
(Choong et al., 2013).Moreover, inmurineMPNmodels, thePI3K/JAK in-
hibitor doublets synergistically improved survival and delayed onset of
splenomegaly (Choong et al., 2013). The use of BEZ235, a dual PI3K/
mTOR inhibitor, alone or in combination with ruxolitinib, in in vitro
and in vivo preclinical models of JAK2 V617F-mutated MPN, also led to
synergism (Bartalucci et al., 2013b). Other classes of agents of interest in-
clude the catalytic mTORC1/2 inhibitors and AKT inhibitors. Currently, a
number of clinical trials involving the use of PI3K/AKT/mTOR inhibitors
alone or in combination are in progress (NCT01730248 and
NCT02493530).8. Telomerase Inhibition
Telomeres, which are nucleoproteins located at the ends of chromo-
somes, maintain genome stability by protecting the ends of chromo-
somes from degradation (Ouellette et al., 2011). Many neoplastic cells
are able to obviate this replicative senescence by activating telomerase,
a reverse transcriptase that maintains telomere length by adding nucleo-
tides to the telomere during cell division. Telomerase inhibition has been
demonstrated to induce this process among neoplastic cells (Ouellette
et al., 2011). Imetelstat, an intravenously administered, 13-mer lipid-
conjugated antisense oligonucleotide that targets the RNA template com-
ponent of telomerase, conferred an 89% overall response rate in a phase 2
study of 18 ET patients forwhom ﬁrst-line therapy had failed (Baerlocher
et al., 2015). Ten of the patients received therapy for a median of
17months, and among the 8 patientswith JAK2V617Fmutations,molec-
ular responses were noted in 7. In a pilot study involving 33MF patients,
half of whom had received prior JAK inhibitor therapy, 21% attained a
complete (n= 4) or partial remission (n= 7; CR, PR) of a median dura-
tion of 18 and 10 months, respectively (Tefferi et al., 2015). Response
rates were higher among those with wild-type ASXL1, as compared to
mutated ASXL1 (32% versus 0%, P = 0.07), and among those with a mu-
tation in SF3B1 or U2AF1, as compared with their wild-type counterparts
(38% versus 4%, P = 0.04). Among the CR patients, bone marrow ﬁbrosis
reversal and molecular responses were noted in 100% and 75%, respec-
tively. Baseline telomere length was not predictive of response. In both
of these studies, grade 3/4 cytopenias occurred in approximately 10–
30% of patients, and many of the patients had low-grade liver function
test abnormalities. In addition to antisense oligonucleotide strategies,
the use of telomerase-targeting small molecules and immunotherapy
represent potential strategies (Mocellin et al., 2013).
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Hedgehog (Hh) is a highly conserved signaling pathway, compo-
nents of which include cell surface receptor Patched-1 (PTCH1), trans-
membrane receptor Smoothened (SMO), and three glioma associated
family transcription factors (GLI) (Khan et al., 2015). It is involved
with multiple essential processes, including stem cell maintenance,
cell cycle regulation, apoptosis, and cellular proliferation, and interacts
with many other pro-survival pathways such as RAS–ERK–MAPK and
PI3K/Akt/mTOR. There is evidence of Hh pathway dysregulation in a
number of malignancies including MPNs, in which a 20–100 fold in-
crease in expression of Hh target genes has been noted in granulocytes
isolated from MPN patients and among preclinical models of PMF
(Bhagwat et al., 2013). In a murine bone marrow transplant model of
ET/MF, the use of the selective SMO inhibitor sonidegib (LDE-225) in
combination with ruxolitinib signiﬁcantly reduced blood counts, mu-
tant allele burden, and bone marrow ﬁbrosis as compared to that ob-
served with ruxolitinib as monotherapy (Bhagwat et al., 2013).
Among 23 intermediate/high-risk MF patients treated with the combi-
nation of these same two agents in the phase 1b portion of a phase
1b/2 study, 65% achieved a ≥50% reduction in palpable spleen length
from baseline (Gupta et al., 2014). In a phase 1a study of SMO inhibitor
PF-04449913 for patients with hematological malignancies (n = 32),
ﬁve of the six MF patients attained stable disease, and the sixth stayed
on study for over a year while achieving durable clinical improvement
with a N50% reduction in extramedullary disease (Jamieson et al.,
2011). For both of these studies, the results from the phase 2 portions
are awaited (NCT01787552 and NCT02226172). In a phase 2 study,
oral SMO inhibitor IPI-926 was administered to 14 MF patients, all of
whom discontinued treatment by 7.5 months primarily due to lack of
effectiveness (Sasaki et al., 2015). There was no signiﬁcant reduction
in symptoms and splenomegaly and insigniﬁcant reductions in JAK2
V617F allele burden and marrow ﬁbrosis. AEs consisted mainly of
low-grade gastrointestinal and hepatic toxicities. The lackluster results
did not support the continuation of the development of this particular
agent. Another SMO inhibitor, erismodegib, is being assessed in combi-
nationwith azacitidine in a phase 1 study for variousmyeloidmalignan-
cies, including MPNs (NCT02129101).
10. PIM Kinase Inhibition
Proviral Integration of Moloney virus (PIM) is a family of pro-
survival serine/threonine kinases, comprising PIM1, PIM2, and PIM3, in-
volved with regulating the cell cycle, cellular metabolism, proliferation,
survival, and cross-talking with Akt kinase (Warfel and Kraft, 2015).
PIM1 expression is induced by JAK2/STAT5 signaling (Fig. 2), suggesting
some involvement of PIM activity in MPN pathogenesis (Lambert et al.,
2014). PIM kinase inhibitors SGI-1776 and AZD1208 inhibited growth
and viability of JAK2 V617F-dependent MPN model and MPN patient
cells in a dose-dependent manner, and activity was enhanced when
used in combination with ruxolitinib. Both of these PIM kinase inhibi-
tors, as single agents, inhibited erythropoietin-independent erythroid
colony formation of primary cells fromMPN patients but not from nor-
mal controls. AZD1208 administered in combination with ruxolitinib
synergistically inhibited colony formation of primary cells from MPN
patients (Lambert et al., 2014). In another set of studies, PIM inhibitor
LGH447 in combination with ruxolitinib led to signiﬁcant modulation
of PIM1/2 and pSTAT3/5, respectively, among JAK2 V617F-mutated
MPN cell lines, and both agents inhibited pERK and pS6 in one of the
cell lines (Saci et al., 2013). This drug combination also resulted in a
greater reduction of overall disease burden and spleen weight than ei-
ther agent alone in a mouse MPN model. The observation of the sup-
pression of MYC protein levels among MPN cell lines after treatment
with various PIM kinase inhibitors provides further support of PIM's
role in MPN pathogenesis (Huang et al., 2014). Using a pooled small
hairpin RNA library screen among an MPN cell line, MYC was identiﬁedas a top therapeutic target in the setting of JAK2 inhibition. Considering
that PIM kinases directly phosphorylate MYC, resulting in stabilization
of MYC, various pan-PIM inhibitors were tested, in combination with
JAK2 inhibitor SAR302503, againstMPN cell lines, demonstrating syner-
gistic MPN cell growth inhibition, apoptosis, and eradication of JAK2
inhibitor-resistant MPN clones. There is currently a phase 1/2 trial eval-
uating pan-PIM inhibitor INCB053914 among patients with MF
(NCT02587598) and a phase 1 trial evaluating another pan-PIM inhibi-
tor PIM447 (formerly LGH447), ruxolitinib, and a CDK 4/6 inhibitor in
doublet and triplet combinations for patients with MF (NCT02370706).
11. Glutaminase Inhibition
Among JAK2 V617F-mutant cells in vitro, as compared with their
wild-type counterparts, there has been the observation of increased ox-
ygen consumption, increased extracellular acidiﬁcation, increased glu-
tamine metabolism, and upregulated glutaminase (Zhan et al., 2015).
Glutaminase expressionwas increased in JAK2 V617F-mutant peripher-
al blood CD34+ cells as compared to JAK2 wild-type progenitor cells
from the same patients MPN patients, and its expression increased fur-
ther with disease progression. The glutaminase inhibitor, BPTES, along
with ruxolitinib, using various laboratory assays, led to an increased
anti-proliferative effect among these JAK2 V617F-mutant cell lines and
MPN patient peripheral blood CD34+ cells from MPN patients than
that of ruxolitinib alone (Zhan et al., 2015). These observations, along
with the knowledge that neoplastic cells generally rely upon aerobic
glycolysis more than normal cells do (i.e., Warburg effect), provide the
rationale for the clinical investigation of the role of glutaminase inhibi-
tor therapy,with orwithout JAK inhibition, amongMPNpatients requir-
ing therapy.
12. Other Therapeutic Strategies
There are multiple other classes of agents, some of which are in clin-
ical development, with potential therapeutic beneﬁt for MPN patients.
These include agents that target heat shock protein-90, isocitrate dehy-
drogenase, and mitogen/extracellular signal-regulated kinase (MEK)
(Weigert et al., 2012; Tefferi et al., 2012; Kong et al., 2014). PRM-151,
a recombinant human pentraxin-2 with anti-ﬁbrosing properties, is
currently being evaluated in a phase 2 clinical trial for patients with
MF (NCT01981850). Aurora A kinase inhibitors, which have been
shown to inducemegakaryocytic polyploidization, induce growth arrest
and apoptosis of a megakaryoblastic cell line, and decrease disease bur-
den in a murine model, are also of great clinical interest (Verstovsek
et al., 2014; Goldenson et al., 2013). A multicenter pilot study involving
the Aurora A kinase inhibitor alisertib for the treatment of MF patients
has recently been launched (NCT02530619).
13. Conclusion
The need for optimal treatment options for many patients with MPN
persists, despite the advent of ruxolitinib. In general, JAK inhibitor mono-
therapy has considerably improved patient well-being, ameliorating
MPNsymptoms and splenomegaly, but disease remission is not an expec-
tation. Given the ability to relieve symptoms, JAK inhibitor therapy may
become an essential cornerstone of combination therapy with other
novel agents, which may address other aspects of disease pathogenesis.
14. Outstanding Questions
Efforts continue to identify relevant, targetable pathogenetic path-
ways in MPNs, with the goal of improving efﬁcacy and decreasing off-
target toxicity of therapy. Further therapeutic efforts may be facilitated
by addressing the following questions or issues: a better understanding
of the mechanisms of action of novel agents; accurate identiﬁcation of
predictive biomarkers of response to therapy; the optimal time to
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heterogeneity of MPNs and that many patients will fare well with cur-
rently established general treatment options, such as phlebotomy, aspi-
rin, and use of cytoreductive agents; how clinical trials may be
judiciously designed and conducted, given the relatively low incidence
of MPNs along with the limitless potential drug combinations; with
new, effective therapies, how allogeneic hematopoietic stem cell trans-
plantation should be incorporated into the treatment paradigm.
15. Search Strategy and Selection Criteria
Data for this Reviewwere identiﬁed by searches of PubMed, the ab-
stract libraries of the American Society of Hematology and the American
Society of Clinical Oncology, and www.clinicaltrials.gov, using the
search terms “myeloproliferative neoplasm” “novel” “targeted therapy”
“pathobiology” and the names of the classes of agents discussed in the
Review.
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